<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04962308</url>
  </required_header>
  <id_info>
    <org_study_id>PRO-nCOV-4003</org_study_id>
    <nct_id>NCT04962308</nct_id>
  </id_info>
  <brief_title>Clinical Trial of Inactivated SARS-CoV-2 Vaccine for Prevention of COVID-19 in Healthy Adults</brief_title>
  <official_title>An Open-label,Phase Ⅳ Clinical Trial to Evaluate the Immunogenicity and Safety of the Inactivated SARS-CoV-2 Vaccine (Vero Cell) in Healthy Population Aged From 18 to 59 Years.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sinovac Research and Development Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sinovac Biotech Co., Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is an open-label phase Ⅳ clinical trial of the inactivated SARS-CoV-2&#xD;
      vaccine(CoronaVac)manufactured by Sinovac Research &amp; Development Co., Ltd. The purpose of&#xD;
      this study is to evaluate the immunogenicity and safety of the Inactivated SARS-CoV-2 Vaccine&#xD;
      (Vero Cell) in Healthy Population Aged From 18 to 59 Years.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is an open-label phase Ⅳ clinical trial in healthy adult aged 18-59 years. The&#xD;
      experimental vaccine was manufactured by Sinovac Research and Development Co.,Ltd.. A total&#xD;
      of 1400 subjects will be enrolled,the safety and immunogenicity of booster immunization were&#xD;
      evaluated in 400 subjects (group A) who received two doses of primary immunization at an&#xD;
      interval of 21 to 31 days. And the safety of booster immunization was evaluated in the&#xD;
      extended safety group (group B), which included 1000 subjects.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 19, 2021</start_date>
  <completion_date type="Anticipated">December 19, 2021</completion_date>
  <primary_completion_date type="Actual">August 19, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Geometric mean titer(GMT) of neutralizing antibody to live SARS-CoV-2</measure>
    <time_frame>1 month after booster immunization</time_frame>
    <description>GMT of the neutralizing antibody to live SARS-CoV-2 within 1month after booster immunization of the Inactivated SARS-CoV-2 vaccine.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety index-incidence of adverse reactions</measure>
    <time_frame>1 month after booster immunization</time_frame>
    <description>Incidence rate of adverse reactions within 1 month after booster immunization of the Inactivated SARS-CoV-2 vaccine</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety index-incidence of serious adverse events</measure>
    <time_frame>1 month after booster immunization</time_frame>
    <description>Incidence rate of serious adverse events within 1 month after booster immunization of the Inactivated SARS-CoV-2 vaccine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seroconversion rate,seropositivity rate and GMI of the neutralizing antibody to SARS-CoV-2</measure>
    <time_frame>1 month after booster immunization</time_frame>
    <description>Seroconversion rate,seropositivity rate and GMI of the neutralizing antibody to SARS-CoV-2 within 1 month after booster immunization of the Inactivated SARS-CoV-2 vaccine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seropositivity rate of IgG antibody</measure>
    <time_frame>1 month after booster immunization</time_frame>
    <description>Seropositivity rate of IgG antibody within 1 month after booster immunization of the Inactivated SARS-CoV-2 vaccine</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">1400</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>Experimental Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>200 subjects in group A1 will receive one dose of booster immunization 3 months after the completion of the second dose of primary immunization of the SARS-CoV-2 Inactivated vaccine.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>200 subjects in group A2 will receive one dose of booster immunization 5 months after the completion of the second dose of primary immunization of the SARS-CoV-2 Inactivated vaccine.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Safety group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1000 subjects in group B will be enrolled and receive 1 dose of booster immunization more than 3 months after the completion of the second dose of primary immunization of the SARS-CoV-2 Inactivated vaccine</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>SARS-CoV-2 Inactivated Vaccine</intervention_name>
    <description>600SU inactivated virus in 0·5 mL of aluminiumhydroxide solution per injection</description>
    <arm_group_label>Experimental Group</arm_group_label>
    <arm_group_label>Safety group</arm_group_label>
    <other_name>CoronaVac</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>The SARS-CoV-2 Inactivated Vaccine</intervention_name>
    <description>600SU inactivated virus in 0·5 mL of aluminiumhydroxide solution per injection</description>
    <arm_group_label>Control Group</arm_group_label>
    <other_name>CoronaVac</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy adults aged 18-59;&#xD;
&#xD;
          -  Have been received two doses of inactivated SARS-CoV-2 vaccine(CoronaVac)manufactured&#xD;
             by Sinovac Research &amp; Development Co., Ltd at an interval of 21 to 31 days for group&#xD;
             A.Have been vaccination two doses of inactivated SARS-CoV-2&#xD;
             vaccine(CoronaVac)manufactured by Sinovac Research &amp; Development Co., Ltd for group B;&#xD;
&#xD;
          -  The subjects can understand and voluntarily sign the informed consent form;&#xD;
&#xD;
          -  Proven legal identity.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of SARS-CoV-2 infection;&#xD;
&#xD;
          -  Any serious adverse reactions that are causally related to vaccination during the&#xD;
             primary immunization of the previous inactivated SARS-CoV-2 vaccine;&#xD;
&#xD;
          -  Severe allergic reactions after primary immunization (including urticaria/rash within&#xD;
             30 minutes after vaccination);&#xD;
&#xD;
          -  Autoimmune disease or immunodeficiency / immunosuppression;&#xD;
&#xD;
          -  Severe chronic diseases, severe cardiovascular diseases, hypertension and diabetes&#xD;
             that cannot be controlled by drugs, liver or kidney diseases, malignant tumors, etc;&#xD;
&#xD;
          -  Severe neurological disease (epilepsy, convulsions or convulsions) or mental illness;&#xD;
&#xD;
          -  Immunosuppressive therapy, cytotoxic therapy, inhaled corticosteroids (excluding&#xD;
             allergic rhinitis corticosteroid spray therapy, acute noncomplicated dermatitis&#xD;
             superficial corticosteroid therapy) within 6 months before primary immunization and&#xD;
             before booster immunization;&#xD;
&#xD;
          -  Already pregnant or are breastfeeding, planning to get pregnant (according to&#xD;
             subjects' self-report and urine pregnancy test results)&#xD;
&#xD;
          -  Receipt of attenuated live vaccines within 14 days prior to booster vaccination;&#xD;
&#xD;
          -  Receipt of inactivated or subunit vaccines within 7 days prior to booster vaccination;&#xD;
&#xD;
          -  Acute diseases or acute exacerbation of chronic diseases within 7 days prior to&#xD;
             booster vaccination;&#xD;
&#xD;
          -  Axillary temperature &gt;37.0°C prior to booster vaccination;&#xD;
&#xD;
          -  According to the investigator's judgment, the subject has any other factors that are&#xD;
             not suitable for participating in the clinical trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>59 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jiang Wu, Master</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Center for Disease Control and Prevention</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jiang Wu, Master</last_name>
    <phone>13381081732</phone>
    <email>wj81732@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Beijing Centers for Diseases Control and Prevention</name>
      <address>
        <city>Beijing</city>
        <zip>100013</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jiang Wu, Master</last_name>
      <phone>64407095</phone>
      <email>wj81732@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Jiang Wu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>July 13, 2021</study_first_submitted>
  <study_first_submitted_qc>July 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 14, 2021</study_first_posted>
  <last_update_submitted>September 22, 2021</last_update_submitted>
  <last_update_submitted_qc>September 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

